Investors
Investors
Cohera Medical Accomplishments
PR-0005
Cohera Medical, Inc., an early-stage company launched in January, 2006, is developing a novel suite of surgical adhesives for the medical industry. The company received CE mark for its lead product, TissuGlu® Surgical Adhesive, in 2011.
A commitment to improving patient care and quality of life.
Unique opportunity for value creation
Cohera Medical’s adhesive technology platform has the potential to create solutions to clinical challenges faced by surgeons and their patients for which there are few options today. The chemistry underlying the technology formulation is straightforward, proprietary, and offers the ability to create multiple product extensions.
A record of success
A strong and experienced leadership team has guided Cohera Medical through its initial funding rounds, raising over $50M since the company’s launch in 2006, including $2M in non-dilutive grant support through the SBIR program. This financing has allowed TissuGlu Surgical Adhesive to progress through its development stages, culminating in CE Mark approval in 2011.
Ready to scale
Cohera has established relationships with key raw material providers and identified a GMP (Good Manufacturing Practices) manufacturing facility. Our lead product, TissuGlu Surgical Adhesive, entered the European market after receiving CE mark in 3Q 2011.
“We view Cohera Medical’s unique lead product and technology chassis as having tremendous potential to meet multiple needs of surgeons and their patients for which there are few options today.”
Marty Calihan, Partner
Bradford Capital Partners
Eyes on the future
Cohera Medical has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to begin a prospective, multicenter, randomized clinical trial for its lead product, TissuGlu Surgical Adhesive in the United States.
The company is also developing new surgical adhesives and sealants that target other medical applications, including their latest innovation, FlexSil™ Surgical Sealant for sealing bowel anastomoses, and a new product for hernia mesh fixation.†
*Disclaimer: TissuGlu Surgical Adhesive received European CE Mark in 2011. Currently, TissuGlu Surgical Adhesive is approved for investigational use only in the United States and is not approved for sale in the U.S. or any other country outside of the EU.
†Disclaimer: Hernia mesh fixation and bowel sealant products are not currently available for sale or distribution and have not been approved by the U.S. FDA or any other country’s regulatory authority. The devices described are currently limited to non-human investigational use only.
FORWARD LOOKING STATEMENTS The forward-looking statements included herein reflect significant assumptions and subjective judgments by the Company’s management concerning anticipated results. These assumptions and judgments may or may not prove to be correct and there can be no assurance that any targets, estimates or forecasts are attainable or will be realized. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from the estimates and forecasts. The forward-looking statements are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are not within the Company’s control. Such statements should not be regarded as a representation or warranty with respect to their accuracy or the accuracy or sufficiency of the underlying assumptions, or that the Company will achieve or is likely to achieve a particular result. Hernia mesh fixation and bowel sealant products are not currently available for sale or distribution and have not been approved by the U.S. FDA or any other country’s regulatory authority. The devices described are currently limited to non-human investigational use only.